spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

UBC APPOINTS BEKKI BROWN PRESIDENT & CHIEF EXECUTIVE OFFICER

UBC

Effective January 1, 2023, Bekki Brown will assume the role of President & Chief Executive Officer of UBC


 
BLUE BELL, P.A., November 10, 2022 – UBC, a biopharmaceutical leader providing integrated clinical, safety, and commercialization services, today announced today that effective January 1, 2023, Bekki Brown, UBC’s Chief Operating Officer, will be elevated to the role of President & Chief Executive Officer.

Bekki’s more than 20 years of senior management experience focused on strategic growth and operational excellence for industry-leading organizations such as Quintiles, INC Research, and Syneos Health, will play an integral role in designing UBC’s long-term market position, expanding their service model, and maintaining their financial strength.

“As we enter the post-COVID world of drug development, we embark on one of the most innovative markets in recent history,” said Patrick Lindsay, President & Chief Executive Officer, UBC. “To best maximize our opportunities, we are now positioning UBC for significant growth, both organically and inorganically. I have the utmost confidence that Bekki will provide the vision, leadership, and management necessary to ensure UBC remains a standard bearer for innovation, quality, and safety in the life sciences industry as we continue to adapt, evolve, and grow.”

In the new year, Mr. Lindsay will join the UBC Board of Directors serving as strategic advisor to the CEO, and the organization, in achieving purposeful growth with a keen focus on identifying inorganic opportunities which support the strategic direction of UBC.
phone +1.215.591.2880
web https://ubc.com/
email 920 Harvest Drive Blue Bell, PA 19422
 
Print this page
Send to a friend
   
spacer
News and Press Releases

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

How streamlining relations between central labs and mobile health providers can get the most from hybrid and decentralised clinical trials
More info >>


White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement